Drugs codes by Medicare payment, 2020
Every code billed to Original Medicare Part B, with how many providers bill it and what it paid.
Top 200 drugs codes
The 200 with the most payment of 261 codes.
Not listed: 130 codes billed by fewer than 11 providers (small cells; each has its own page with the count).
| observed | calculated | calculated | calculated | calculated | calculated | ||
|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,954 | $2,270,531,860 | 22% | 3,076,947 | 714 | |
| J2778 | Injection, ranibizumab, 0.1 mg | 1,474 | $845,963,540 | 8.2% | 3,179,518 | 956 | |
| J9271 | Injection, pembrolizumab, 1 mg | 1,467 | $753,229,592 | 7.3% | 19,161,479 | 10,830 | |
| J0897 | Injection, denosumab, 1 mg | 9,672 | $696,220,853 | 6.8% | 45,291,470 | 2,640 | |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 1,037 | $490,770,177 | 4.8% | 11,127,563 | 8,425 | |
| 90662 | Descriptor not shown (CPT code) | 86,650 | $434,202,465 | 4.2% | 7,416,987 | 52 | |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 662 | $266,528,248 | 2.6% | 41,410,519 | 46,400 | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,424 | $254,958,889 | 2.5% | 6,192,993 | 3,130 | |
| 90694 | Descriptor not shown (CPT code) | 34,250 | $249,786,099 | 2.4% | 4,271,851 | 68 | |
| J9312 | Injection, rituximab, 10 mg | 935 | $241,413,523 | 2.3% | 3,318,875 | 2,920 | |
| J2505 | Injection, pegfilgrastim, 6 mg | 1,545 | $240,348,325 | 2.3% | 78,284 | 39 | |
| J9299 | Injection, nivolumab, 1 mg | 473 | $191,923,683 | 1.9% | 8,734,653 | 15,223 | |
| 90670 | Descriptor not shown (CPT code) | 32,863 | $181,274,229 | 1.8% | 808,232 | 18 | |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 728 | $178,399,237 | 1.7% | 11,424,332 | 11,930 | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 3,095 | $159,380,343 | 1.5% | 33,780,592 | 7,090 | |
| 90732 | Descriptor not shown (CPT code) | 52,471 | $153,615,371 | 1.5% | 1,320,291 | 19 | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 4,554 | $131,820,652 | 1.3% | 756,175 | 134 | |
| J2357 | Injection, omalizumab, 5 mg | 511 | $99,168,050 | 0.96% | 3,385,953 | 4,845 | |
| J2785 | Injection, regadenoson, 0.1 mg | 6,118 | $94,574,893 | 0.92% | 2,036,102 | 212 | |
| J3262 | Injection, tocilizumab, 1 mg | 422 | $87,948,996 | 0.85% | 21,567,393 | 45,240 | |
| J7320 | Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg | 876 | $84,782,292 | 0.82% | 6,356,624 | 3,450 | |
| J9035 | Injection, bevacizumab, 10 mg | 2,287 | $78,218,831 | 0.76% | 1,322,264 | 175 | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 1,214 | $75,224,347 | 0.73% | 25,492,070 | 14,093 | |
| J7326 | Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | 1,652 | $74,827,174 | 0.73% | 82,912 | 33 | |
| J0179 | Injection, brolucizumab-dbll, 1 mg | 501 | $68,527,884 | 0.67% | 276,257 | 384 | |
| J2350 | Injection, ocrelizumab, 1 mg | 95 | $66,620,721 | 0.65% | 1,634,466 | 12,601 | |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 350 | $64,929,749 | 0.63% | 2,022,903 | 4,289 | |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 396 | $64,095,271 | 0.62% | 2,045,366 | 3,365 | |
| J9145 | Injection, daratumumab, 10 mg | 206 | $57,759,412 | 0.56% | 1,342,361 | 4,580 | |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 309 | $53,854,100 | 0.52% | 3,406,403 | 7,500 | |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 153 | $47,550,254 | 0.46% | 1,469,273 | 4,830 | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 1,350 | $46,610,144 | 0.45% | 53,613,506 | 29,250 | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 1,278 | $45,620,690 | 0.44% | 5,910,507 | 2,413 | |
| J9041 | Injection, bortezomib, 0.1 mg | 489 | $43,404,482 | 0.42% | 1,225,716 | 2,030 | |
| Q4159 | Affinity, per square centimeter | 58 | $41,215,317 | 0.40% | 61,331 | 776 | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 1,318 | $38,726,952 | 0.38% | 47,654,561 | 23,970 | |
| 90682 | Descriptor not shown (CPT code) | 13,876 | $37,403,971 | 0.36% | 629,564 | 27 | |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 286 | $36,589,755 | 0.36% | 5,119,675 | 12,863 | |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 251 | $34,385,046 | 0.33% | 140,545 | 468 | |
| J3357 | Ustekinumab, for subcutaneous injection, 1 mg | 66 | $34,194,686 | 0.33% | 230,896 | 2,138 | |
| J7322 | Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | 619 | $34,040,236 | 0.33% | 1,352,538 | 1,560 | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 154 | $29,905,893 | 0.29% | 598,006 | 2,885 | |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 1,088 | $29,664,686 | 0.29% | 2,046,814 | 1,152 | |
| J2323 | Injection, natalizumab, 1 mg | 59 | $29,415,516 | 0.29% | 1,854,195 | 17,420 | |
| J7325 | Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 1,867 | $27,510,865 | 0.27% | 3,245,233 | 1,248 | |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 525 | $25,947,558 | 0.25% | 165,656 | 252 | |
| J7327 | Hyaluronan or derivative, monovisc, for intra-articular injection, per dose | 996 | $25,901,925 | 0.25% | 44,137 | 31 | |
| J7324 | Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose | 1,753 | $25,384,687 | 0.25% | 242,640 | 89 | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | 2,052 | $25,269,540 | 0.25% | 225,949 | 79 | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 745 | $25,194,887 | 0.24% | 3,763,475 | 3,660 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Descriptions of HCPCS Level II codes are the official CMS descriptors, shown verbatim; CPT codes show a ClaimLight category in place of the descriptor. Data year 2020.
Original Medicare Part B fee-for-service only; CMS suppresses provider lines with fewer than 11 beneficiaries. How these figures are computed